Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil

Katayoun Djazayeri, Z. Szilvássy, Klára Benko, Bernadett Rózsa, Boglárka Szabó, A. József Szentmiklósi, Ilona Benko

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Haematopoietic colony-stimulating factors are used frequently to moderate myelotoxicity, but administration of granulocyte-colony-stimulating factor (G-CSF) prior to chemotherapy actually may worsen the toxic effects on bone marrow. This is important in the design of clinical cancer treatment protocols. Previously, we found that rosiglitazone may protect granulocyte-macrophage progenitor cells (CFU-GM) against damage caused by a single dose of 5-fluorouracil (5-FU). Our new studies are designed to evaluate whether rosiglitazone has similar beneficial effects on bone marrow preservation when administered concurrently with repeated, daily doses of 5-FU while restricting regeneration time. Myelotoxicity characterized by the decrease in cellularity, frequency of granulocyte-macrophage progenitor cells and CFU-GM content of femoral bone marrow in mice. Five-day oral rosiglitazone pre-treatment decreased the susceptibility of granulocyte-macrophage progenitors to 5-FU damage. Significantly, more CFU-GM cells survived after the single intraperitoneal dose of 5-FU (100 mg kg-1). The increased frequency of CFU-GM cells with their intensive proliferation allowed faster restoration of the damaged CFU-GM compartment than was seen in the case of repeated daily administration of the cytostatic drug (25 or 50 mg kg-1) together with rosiglitazone for 7 consecutive days. The expansion of the CFU-GM compartment was 3 times and 50 times greater in the combined-treated mice than in their counterparts treated with repeated doses of 5-FU alone, although differences in absolute neutrophil counts were not significant. In conclusion, our results indicated that rosiglitazone has protective effects on bone marrow progenitor cells even after daily 5-FU treatment but further studies are warranted to evaluate the optimal treatment schedules.

Original languageEnglish
Pages (from-to)156-161
Number of pages6
JournalPharmacological Research
Volume53
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

rosiglitazone
Granulocyte-Macrophage Progenitor Cells
Fluorouracil
Insulin
Bone Marrow
Antineoplastic Protocols
Colony-Stimulating Factors
Poisons
Cytostatic Agents
Granulocyte Colony-Stimulating Factor

Keywords

  • Bone marrow toxicity
  • Cancer treatment protocol
  • CFU-GM
  • Myeloprotective
  • Progenitor cells
  • Thiazolidinediones

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil. / Djazayeri, Katayoun; Szilvássy, Z.; Benko, Klára; Rózsa, Bernadett; Szabó, Boglárka; Szentmiklósi, A. József; Benko, Ilona.

In: Pharmacological Research, Vol. 53, No. 2, 02.2006, p. 156-161.

Research output: Contribution to journalArticle

Djazayeri, Katayoun ; Szilvássy, Z. ; Benko, Klára ; Rózsa, Bernadett ; Szabó, Boglárka ; Szentmiklósi, A. József ; Benko, Ilona. / Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil. In: Pharmacological Research. 2006 ; Vol. 53, No. 2. pp. 156-161.
@article{dfb20fabc30c450b8d3a4b4511654083,
title = "Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil",
abstract = "Haematopoietic colony-stimulating factors are used frequently to moderate myelotoxicity, but administration of granulocyte-colony-stimulating factor (G-CSF) prior to chemotherapy actually may worsen the toxic effects on bone marrow. This is important in the design of clinical cancer treatment protocols. Previously, we found that rosiglitazone may protect granulocyte-macrophage progenitor cells (CFU-GM) against damage caused by a single dose of 5-fluorouracil (5-FU). Our new studies are designed to evaluate whether rosiglitazone has similar beneficial effects on bone marrow preservation when administered concurrently with repeated, daily doses of 5-FU while restricting regeneration time. Myelotoxicity characterized by the decrease in cellularity, frequency of granulocyte-macrophage progenitor cells and CFU-GM content of femoral bone marrow in mice. Five-day oral rosiglitazone pre-treatment decreased the susceptibility of granulocyte-macrophage progenitors to 5-FU damage. Significantly, more CFU-GM cells survived after the single intraperitoneal dose of 5-FU (100 mg kg-1). The increased frequency of CFU-GM cells with their intensive proliferation allowed faster restoration of the damaged CFU-GM compartment than was seen in the case of repeated daily administration of the cytostatic drug (25 or 50 mg kg-1) together with rosiglitazone for 7 consecutive days. The expansion of the CFU-GM compartment was 3 times and 50 times greater in the combined-treated mice than in their counterparts treated with repeated doses of 5-FU alone, although differences in absolute neutrophil counts were not significant. In conclusion, our results indicated that rosiglitazone has protective effects on bone marrow progenitor cells even after daily 5-FU treatment but further studies are warranted to evaluate the optimal treatment schedules.",
keywords = "Bone marrow toxicity, Cancer treatment protocol, CFU-GM, Myeloprotective, Progenitor cells, Thiazolidinediones",
author = "Katayoun Djazayeri and Z. Szilv{\'a}ssy and Kl{\'a}ra Benko and Bernadett R{\'o}zsa and Bogl{\'a}rka Szab{\'o} and Szentmikl{\'o}si, {A. J{\'o}zsef} and Ilona Benko",
year = "2006",
month = "2",
doi = "10.1016/j.phrs.2005.10.004",
language = "English",
volume = "53",
pages = "156--161",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil

AU - Djazayeri, Katayoun

AU - Szilvássy, Z.

AU - Benko, Klára

AU - Rózsa, Bernadett

AU - Szabó, Boglárka

AU - Szentmiklósi, A. József

AU - Benko, Ilona

PY - 2006/2

Y1 - 2006/2

N2 - Haematopoietic colony-stimulating factors are used frequently to moderate myelotoxicity, but administration of granulocyte-colony-stimulating factor (G-CSF) prior to chemotherapy actually may worsen the toxic effects on bone marrow. This is important in the design of clinical cancer treatment protocols. Previously, we found that rosiglitazone may protect granulocyte-macrophage progenitor cells (CFU-GM) against damage caused by a single dose of 5-fluorouracil (5-FU). Our new studies are designed to evaluate whether rosiglitazone has similar beneficial effects on bone marrow preservation when administered concurrently with repeated, daily doses of 5-FU while restricting regeneration time. Myelotoxicity characterized by the decrease in cellularity, frequency of granulocyte-macrophage progenitor cells and CFU-GM content of femoral bone marrow in mice. Five-day oral rosiglitazone pre-treatment decreased the susceptibility of granulocyte-macrophage progenitors to 5-FU damage. Significantly, more CFU-GM cells survived after the single intraperitoneal dose of 5-FU (100 mg kg-1). The increased frequency of CFU-GM cells with their intensive proliferation allowed faster restoration of the damaged CFU-GM compartment than was seen in the case of repeated daily administration of the cytostatic drug (25 or 50 mg kg-1) together with rosiglitazone for 7 consecutive days. The expansion of the CFU-GM compartment was 3 times and 50 times greater in the combined-treated mice than in their counterparts treated with repeated doses of 5-FU alone, although differences in absolute neutrophil counts were not significant. In conclusion, our results indicated that rosiglitazone has protective effects on bone marrow progenitor cells even after daily 5-FU treatment but further studies are warranted to evaluate the optimal treatment schedules.

AB - Haematopoietic colony-stimulating factors are used frequently to moderate myelotoxicity, but administration of granulocyte-colony-stimulating factor (G-CSF) prior to chemotherapy actually may worsen the toxic effects on bone marrow. This is important in the design of clinical cancer treatment protocols. Previously, we found that rosiglitazone may protect granulocyte-macrophage progenitor cells (CFU-GM) against damage caused by a single dose of 5-fluorouracil (5-FU). Our new studies are designed to evaluate whether rosiglitazone has similar beneficial effects on bone marrow preservation when administered concurrently with repeated, daily doses of 5-FU while restricting regeneration time. Myelotoxicity characterized by the decrease in cellularity, frequency of granulocyte-macrophage progenitor cells and CFU-GM content of femoral bone marrow in mice. Five-day oral rosiglitazone pre-treatment decreased the susceptibility of granulocyte-macrophage progenitors to 5-FU damage. Significantly, more CFU-GM cells survived after the single intraperitoneal dose of 5-FU (100 mg kg-1). The increased frequency of CFU-GM cells with their intensive proliferation allowed faster restoration of the damaged CFU-GM compartment than was seen in the case of repeated daily administration of the cytostatic drug (25 or 50 mg kg-1) together with rosiglitazone for 7 consecutive days. The expansion of the CFU-GM compartment was 3 times and 50 times greater in the combined-treated mice than in their counterparts treated with repeated doses of 5-FU alone, although differences in absolute neutrophil counts were not significant. In conclusion, our results indicated that rosiglitazone has protective effects on bone marrow progenitor cells even after daily 5-FU treatment but further studies are warranted to evaluate the optimal treatment schedules.

KW - Bone marrow toxicity

KW - Cancer treatment protocol

KW - CFU-GM

KW - Myeloprotective

KW - Progenitor cells

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=29344471012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344471012&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2005.10.004

DO - 10.1016/j.phrs.2005.10.004

M3 - Article

VL - 53

SP - 156

EP - 161

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 2

ER -